Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics (LUCD)
NASDAQ:LUCD
Lucid Diagnostics (LUCD) Stock Price & Analysis
233 Followers
LUCD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.63 - $1.85
Previous Close$0.95
Volume137.54K
Average Volume (3M)230.68K
Market Cap
$46.05M
Enterprise Value$21.55M
Total Cash (Recent Filing)$39.52M
Total Debt (Recent Filing)$13.78M
Price to Earnings (P/E)-0.7
Beta1.28
Next Earnings
Nov 11, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding48,244,798
10 Day Avg. Volume350,160
30 Day Avg. Volume230,678
Standard Deviation0.19
R-Squared0.17
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)5.46
Price to Sales (P/S)121.57
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue33.99
Enterprise Value/Gross Profit57.16
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$3.83Price Target Upside314.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Lucid Diagnostics News
PremiumCompany Announcements
Lucid Diagnostics Insights: Performance and Outlook Update
PremiumCompany Announcements
Lucid Diagnostics Raises $11.6M Through Preferred Stock Sale
PremiumCompany Announcements
Lucid Diagnostics Highlights Promising EsoGuard Study ResultsBulls Say, Bears Say
Bulls Say
Financial PerformanceAnalysts project Lucid's revenue to grow substantially in 2024, driven by high growth expectations and the significant market opportunity for its novel diagnostic technology.
Market OpportunityTwo leading gastroenterology associations now support Lucid's products as an acceptable alternative to endoscopy, potentially increasing market adoption and boosting revenue.
Product SuperiorityLucid Diagnostics Inc.'s EsoGuard and EsoCheck products offer a superior method for detecting Barrett's esophagus, with higher sensitivity compared to competing technologies, positioning them as potential leaders in the market.
Bears Say
Financial PerformanceLUCD missed consensus revenue in 4Q23.
Product EfficacyCompetitor Exact Sciences reported lower sensitivity in their Oncoguard test for detecting short segment Barrett's esophagus, which is a limitation for its use in widespread screening.
Sales PerformanceEsoGuard test volume declined 15% sequentially in 4Q23.
---
Ownership Overview
69.55% Insiders
1.52% Mutual Funds
1.17% Other Institutional Investors
27.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LUCD FAQ
What was Lucid Diagnostics’s price range in the past 12 months?
Lucid Diagnostics lowest stock price was $0.63 and its highest was $1.85 in the past 12 months.
What is Lucid Diagnostics’s market cap?
Currently, no data Available
When is Lucid Diagnostics’s upcoming earnings report date?
Lucid Diagnostics’s upcoming earnings report date is Nov 11, 2024 which is in 181 days.
How were Lucid Diagnostics’s earnings last quarter?
Lucid Diagnostics released its earnings results on May 13, 2024. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.24 by -$0.75.
Is Lucid Diagnostics overvalued?
According to Wall Street analysts Lucid Diagnostics’s price is currently Undervalued.
Does Lucid Diagnostics pay dividends?
Lucid Diagnostics does not currently pay dividends.
What is Lucid Diagnostics’s EPS estimate?
Lucid Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lucid Diagnostics have?
Lucid Diagnostics has 49,784,462 shares outstanding.
What happened to Lucid Diagnostics’s price movement after its last earnings report?
Lucid Diagnostics reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.24. Following the earnings report the stock price went up 1.064%.
Which hedge fund is a major shareholder of Lucid Diagnostics?
Currently, no hedge funds are holding shares in LUCD
---
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.83 (314.05% Upside)
$3.83 (314.05% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.90%
12-Months-Change
Fundamentals
Return on Equity
-255.60%
Trailing 12-Months
Asset Growth
-34.76%
Trailing 12-Months
Company Description
Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
---
LUCD Earnings Call
Q4 2024
0:00 / 0:00
---
LUCD Stock 12 Month Forecast
Average Price Target
$3.83
▲(314.05% Upside)
Technical Analysis
Best Analysts Covering LUCD
1 Year
1 Year Success Rate
2/16 ratings generated profit
1 Year Average Return
-34.18%
reiterated a buy rating 2 days ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -34.18% per trade.
---